Highlights
- ACES Diagnostics, Inc. filed a Form D amendment June 25 showing its $3.6 million private offering is fully subscribed with 27 investors.
- The company lists 4949 E. Lincoln Dr., No. 5, Paradise Valley as its address of record, with Tammy Crawford as executive officer and director.
- Background research indicates the company is developing LymeSeek, a Lyme disease diagnostic tool targeting FDA clearance by the third quarter of 2026.
- The minimum investment accepted was $25,000 and no non-accredited investors participated in the raise.
ACES Diagnostics, Inc., a Delaware-incorporated diagnostics company with a Paradise Valley address of record, has closed a $3.6 million private securities offering, according to an amended Form D filed with the SEC on June 25.
The filing, accession number 0002039838-26-000003, shows the total offering amount and total amount sold are both listed at $3.6 million, with $0 remaining. The raise drew 27 investors, none of them non-accredited, at a minimum investment of $25,000. The date of first sale is listed as June 12, 2024.
Tammy Crawford is named as the company's sole executive officer and director in the filing. The company's address of record is 4949 E. Lincoln Dr., No. 5, Paradise Valley, AZ 85253.
According to AZBio, ACES Diagnostics is developing LymeSeek, a Lyme disease diagnostic tool developed in collaboration with Tulane University and the nonprofit Focus on Lyme. The publication reports the test claims over 90% accuracy and can detect infection within 14 days post-infection, compared to previous tests it describes as less than 50% accurate in early stages. Crawford and co-founder Holly Ahern both have daughters who battled Lyme disease, per the same report.
Who is behind ACES Diagnostics?
Tammy Crawford is listed as the sole executive officer and director in the SEC filing. AZBio identifies Crawford as CEO and notes the company's advisory board includes experts from Johns Hopkins University, Columbia University, and Tulane University. The company is incorporated in Delaware and organized in 2024.
The AZBio report states ACES Diagnostics is pursuing FDA clearance with a target availability date of the third quarter of 2026.
Sources
Every factual claim in this article traces to one of the sources below. See how we work for the editorial process.
Authored by The Scottsdale Signal. Drafted by AI from primary-source material under our beat-specific editorial guides; reviewed by humans before publish under our five-gate process. Sources retrieved at 26/06/2026 10:38. Every claim traces to a source.
